Does pharmacogenomics obviate the need for race-based treatment and screening?
Let’s say that drug A works better for one race than another. Or that disease prevalence is more common for some races than others. Despite the goal to be color-blind in medicine, racial information can prove useful. For instance, sickle cell disease is much more common among African Americans in the US than other races.…